常规经皮冠状动脉介入治疗中生物可吸收支架与金属支架的比较
该研究为研究者发起的随机试验,纳入1845例接受PCI的患者,随机分配至依维莫司洗脱生物可吸收血管支架组(924例)或依维莫司洗脱金属支架组(921例)。主要终点为靶血管失败(心源性死亡、靶血管心肌梗死或靶血管血运重建的复合终点)。中位随访707天,支架组与金属支架组的靶血管失败率分别为11.7%和10.7%(HR 1.12,95%CI 0.85-1.48,P=0.43),无显著差异。但生物可吸收支架组的确定性或可能性器械血栓发生率显著高于金属支架组(2年累积3.5% vs 0.9%,HR 3.87,95%CI 1.78-8.42,P<0.001)。
要点
- 在1845例常规PCI患者中,生物可吸收支架组与金属支架组的2年靶血管失败累积发生率分别为11.7%和10.7%,无显著差异(HR 1.12,95%CI 0.85-1.48,P=0.43)。
- 生物可吸收支架组的2年确定性或可能性器械血栓累积发生率为3.5%,显著高于金属支架组的0.9%(HR 3.87,95%CI 1.78-8.42,P<0.001)。
- 生物可吸收支架组的靶血管心肌梗死2年累积发生率为5.5%,金属支架组为3.2%;靶血管血运重建率分别为8.7%和7.5%。
- 心源性死亡在生物可吸收支架组和金属支架组的2年累积发生率分别为2.0%和2.7%。
- 数据与安全监察委员会因安全性担忧建议提前报告研究结果。
适用人群与场景
- 接受经皮冠状动脉介入治疗(PCI)的常规临床实践患者,共1845例,随机分配至生物可吸收血管支架组(924例)或金属支架组(921例)。
处置流程与药物剂量
- 生物可吸收血管支架组使用依维莫司洗脱生物可吸收血管支架;金属支架组使用依维莫司洗脱金属支架。
红旗征与不能漏的情况
- 生物可吸收支架组器械血栓发生率显著高于金属支架组(2年累积3.5% vs 0.9%,HR 3.87,95%CI 1.78-8.42,P<0.001),数据与安全监察委员会因安全性担忧建议提前报告研究结果。
研究设计与关键结果
- 研究类型为研究者发起的随机试验,样本量1845例,比较依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架在常规PCI中的效果。
- 主要终点靶血管失败(心源性死亡、靶血管心肌梗死或靶血管血运重建的复合终点)在生物可吸收支架组发生105例,金属支架组94例;2年累积事件率分别为11.7%和10.7%(HR 1.12,95%CI 0.85-1.48,P=0.43),无显著差异。
- 心源性死亡在生物可吸收支架组发生18例,金属支架组23例;2年累积事件率分别为2.0%和2.7%。
- 靶血管心肌梗死 在生物可吸收支架组发生48例,金属支架组30例;2年累积事件率分别为5.5%和3.2%。
- 靶血管血运重建在生物可吸收支架组发生76例,金属支架组65例;2年累积事件率分别为8.7%和7.5%。
- 确定性或可能性器械血栓在生物可吸收支架组发生31例,金属支架组8例;2年累积事件率分别为3.5%和0.9%(HR 3.87,95%CI 1.78-8.42,P<0.001)。
- 中位随访时间为707天。
证据类型、等级与局限
- 证据类型为随机对照试验(RCT),由Abbott Vascular资助,临床试验注册号NCT01858077。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在常规PCI患者中,使用生物可吸收血管支架与金属支架相比,靶血管失败率无显著差异,但生物可吸收支架的器械血栓发生率更高。
- 数据与安全监察委员会因安全性担忧建议提前报告研究结果,该报告提供终点事件的描述性信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice.
METHODS: We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients). The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). The data and safety monitoring board recommended early reporting of the study results because of safety concerns. This report provides descriptive information on end-point events.
RESULTS: The median follow-up was 707 days. Target-vessel failure occurred in 105 patients in the scaffold group and in 94 patients in the stent group (2-year cumulative event rates, 11.7% and 10.7%, respectively; hazard ratio, 1.12; 95% confidence interval [CI], 0.85 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses. Cardiac death occurred in 18 patients in the scaffold group and in 23 patients in the stent group (2-year cumulative event rates, 2.0% and 2.7%, respectively), target-vessel myocardial infarction occurred in 48 patients in the scaffold group and in 30 patients in the stent group (2-year cumulative event rates, 5.5% and 3.2%), and target-vessel revascularization occurred in 76 patients in the scaffold group and in 65 patients in the stent group (2-year cumulative event rates, 8.7% and 7.5%). Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001).
CONCLUSIONS: In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .).
参考来源
- Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017. PMID: 28402237. doi:10.1056/NEJMoa1614954
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。